Engineered immune cells take aim at stubborn autoimmune disorder

NCT ID NCT07599280

Not yet recruiting Disease control Sponsor: Jian Zhu Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new therapy called universal STAR-T cells in about 6 adults with autoimmune thrombocytopenia (low platelets) that hasn't responded to standard treatments. The cells are designed to target and calm the overactive immune system. The main goals are to check safety and see if the treatment can improve platelet counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Universal STAR-T cells (a type of engineered immune cell)
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-treat autoimmune low platelet counts.
What could go wrong: This is a very early Phase 1 trial with only 6 participants, so results may not apply broadly. Risks include severe immune reactions or lack of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA

Contacts and locations

Locations

No. 28, Fuxing Road, Haidian District, Beijing, China.

Haidian, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.